Agamree

News

Angelini CEO Sergio Marullo di Condojanni

Angelini seeks US beachhead with $4.1bn Catalyst buy

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.

News

Santhera's DMD drug poised for wider rollout in Germany

Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.

News

Wheelchair sign with trees in background

Santhera preps UK Duchenne drug launch after NICE says yes

Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.

News

Price deal opens door to NHS use of Santhera DMD drug

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.

News

Santhera debuts DMD drug Agamree in Germany

Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.

Angelini seeks US beachhead with $4.1bn Catalyst buy

Santhera's DMD drug poised for wider rollout in Germany

Santhera preps UK Duchenne drug launch after NICE says yes

Price deal opens door to NHS use of Santhera DMD drug

Santhera debuts DMD drug Agamree in Germany

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Agamree

Editor's Picks